IL-1 blockers such as canakinumab (anti-IL-1β antibody) and anakinra (recombinant IL-1R antagonist) are effective against various autoinflammatory diseases including scleritis, Kawasaki disease, osteoarthritis, rheumatoid arthritis, and psoriasis [56–58]. The gene discussed is IL1R1; the disease is rheumatoid arthritis.